Curative Efficacy of Gemcitabine combined with Nida Platinum in treatment of Patients with Advanced Non-small Cell Lung Cancer and the Effects of Serum Tumor Markers
XU Yang, CHEN Dan, LI Fanmin
Leshan People's Hospital, Sichuan Leshan 614000, China
Abstract：Objective: To study curative efficacy of gemcitabine combined with nida platinum in treatment of patients with advanced non-small cell lung cancer and its effects on the effect of serum tumor markers. Methods: 150 patients of late nonsmall cell lung who received therapy from July 2016 to December 2017 were selected as research objects. 75 cases were randomly divided into observation group and 75 in control group. The observation group was treated with gemcitabine combined with nidaliplatin. The control group was treated with cisplatin. The clinical efficacy and quality of life of the two groups were compared. Two groups of patients were recorded before and after treatment of cancer embryo antigen (CEA), carbohydrate antigen 125 (CA125), cytokeratin fragment antigen 21-1 (CYFRA21-1), and neuron specific enolase (NSE). The adverse reactions of the two groups were recorded. The survival time of the two groups was recorded. Results: After treatment, the effective rate was 54.67%, significantly higher than 33.33% in the control group, and the difference was statistically significant (P<0.05). Before treatment, there was no significant difference in the indexes of the two groups. After treatment, both groups showed a decrease in each index level, which was statistically significant (P<0.05). Observation group CEA, CA125 and cyfra21-1 were both lower than the control group, and the difference was statistically significant (P<0.05). After treatment, there was no significant difference in NSE level between the two groups (P>0.05). After treatment, there was no statistically significant difference between the two groups. The ECOG score of observation group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the difference between the two groups in the survival period, and the observation group was significantly higher than the control group with no progress in survival and median survival, and the difference was statistically significant (P<0.05). The incidence of hair loss, nausea and vomiting in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of thrombocytopenia, leukocyte decline, hemoglobin reduction, hepatotoxicity, phlebitis and constipation in both groups (P>0.05). Conclusion: The treatment of patients with advanced non-small cell lung cancer treated by gemcitabine combined with nidaplatin is more effective, with less adverse reactions, and the patient can tolerate the disease, and it is worth promoting the application.
徐杨, 陈丹, 李凡敏. 吉西他滨联合奈达铂对晚期非小细胞肺癌患者疗效及血清肿瘤标志物的影响[J]. 河北医学, 2018, 24(7): 1174-1177.
XU Yang, CHEN Dan, LI Fanmin. Curative Efficacy of Gemcitabine combined with Nida Platinum in treatment of Patients with Advanced Non-small Cell Lung Cancer and the Effects of Serum Tumor Markers. HeBei Med, 2018, 24(7): 1174-1177.
2018, Vol. 24 
冀公网安备13080202000677号